Combined pharmaceutical composition for treating small cell lung cancer
AssigneesChia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing Shunxin Pharmaceuticals Co., LTD. of Chiatai Tianqing Pharmaceutical Group
InventorsShanchun WANG, Xunqiang WANG, Ding YU, Wenwen LIU, Chao SHU, Mengxue FAN
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of biomedicine and relates to a combined pharmaceutical composition used for treating small cell lung cancer, the composition comprising an anti-PD-L1 antibody and anlotinib, and having good anti-small cell lung cancer activity.
Claims22
A combined pharmaceutical composition for use in treating small cell lung cancer, comprising an anti-PD-L1 antibody and anlotinib, wherein the anti-PD-L1 antibody comprises an amino acid sequence as follows:
- a heavy chain CDR1 region selected from the group consisting of SEQ ID NO:
- 1 and SEQ ID NO:
- 4;
- a heavy chain CDR2 region selected from the group consisting of SEQ ID NO:
- 2 and SEQ ID NO:
- 5;
- a heavy chain CDR3 region selected from the group consisting of SEQ ID NO:
- 3 and SEQ ID NO 6;
- a light chain CDR1 region selected from the group consisting of SEQ ID NO:
- 7 and SEQ ID NO:
- 10;
- a light chain CDR2 region selected from the group consisting of SEQ ID NO:
- 8 and SEQ ID NO:
- 11;
- and a light chain CDR3 region selected from the group consisting of SEQ ID NO:
- 9 and SEQ ID NO:
- 12.
7-11. (canceled)
A kit for use in treating small cell lung cancer, comprising a pharmaceutical composition of an anti-PD-L1 antibody, a pharmaceutical composition of anlotinib, and an instruction for combined use of the anti-PD-L1 antibody and anlotinib in treating small cell lung cancer, wherein the anti-PD-L1 antibody comprises an amino acid sequence as follows:
- a heavy chain CDR1 region selected from the group consisting of SEQ ID NO:
- 1 and SEQ ID NO:
- 4;
- a heavy chain CDR2 region selected from the group consisting of SEQ ID NO:
- 2 and SEQ ID NO:
- 5;
- a heavy chain CDR3 region selected from the group consisting of SEQ ID NO:
- 3 and SEQ ID NO:
- 6;
- a light chain CDR1 region selected from the group consisting of SEQ ID NO:
- 7 and SEQ ID NO:
- 10;
- a light chain CDR2 region selected from the group consisting of SEQ ID NO:
- 8 and SEQ ID NO:
- 11;
- and a light chain CDR3 region selected from the group consisting of SEQ ID NO:
- 9 and SEQ ID NO:
- 12.
14-15. (canceled)
Dependencies are inferred from the claim text.